Strongest evidence:
- Increased 25-hydroxyvitamin D levels: 12 of 14 studies (high evidence) show benefit at doses of 400–4000 IU/day.
- Reduced parathyroid hormone: 3 of 4 studies (high evidence) show small effects at up to 5,000 IU/day.
- Improved insulin sensitivity: 6 of 9 studies (moderate evidence) show small-to-moderate effects at 1000–4000 IU/day.
- Reduced inflammation (IL-6, CRP, TNF-α, general inflammation): 4–5 of 5–8 studies (moderate evidence) show small-to-moderate reductions, with doses typically 200–5000 IU/day.
- Improved quality of life: 6 of 6 studies (moderate evidence) show small effects, notably at 4000 IU/day or 60,000 IU/week in clinical populations.
- Reduced triglycerides and HOMA-IR: 3–4 of 5–7 studies (moderate evidence) show small improvements in metabolic markers.
- Reduced pain: 3 of 4 studies (moderate evidence) show small-to-moderate effects, often at 800 IU/day.
Mixed or weaker evidence: No outcomes with low or very low evidence strength were found in the top 12 syntheses. However, many outcomes classified as moderate strength show neutral findings in 20–40% of studies, particularly in replete or pediatric populations, suggesting effects are context-dependent.
Effective dose patterns: Across multiple outcomes, daily doses of 1000–5000 IU/day (or weekly equivalents like 60,000 IU) are most commonly associated with beneficial effects. For vitamin D level improvement and inflammatory markers, lower doses (200–800 IU/day) also show benefit in some studies. No consistent dose-response relationship was established due to heterogeneity in study designs.
Population insights: Beneficial effects are most consistent in vitamin D-deficient individuals, older adults, and clinical populations (e.g., diabetes, PCOS, inflammatory conditions, chronic pain). Benefits are less clear or absent in replete, healthy, or pediatric populations. For example, neutral findings were noted in bariatric surgery patients (PTH), overweight children (triglycerides, TNF-α), and kidney transplant recipients (25(OH)D increase).
Notable caveats:
- Publication bias is flagged across nearly all outcomes — null-result studies are less likely to be published, potentially inflating the apparent benefit.
- Many studies did not specify the form of vitamin D (D2 vs. D3); D3 may be more effective.
- Median study durations are short (30–90 days for most outcomes), limiting conclusions about long-term effects.
- Baseline vitamin D status was not consistently reported, making it difficult to separate deficiency correction from pharmacological effects.
- Some studies had small sample sizes or did not report dosing details, reducing precision.